Navigation Links
YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial -

MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced results of secondary endpoint data from its 99 patient, randomized, placebo-controlled, multi-center Phase IIb trial (DLXLEF-AP4) with AeroLEF(TM). AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. YM previously announced that this trial had successfully achieved its primary endpoint, the summed pain intensity difference/pain relief scores (SPRID4) during the 4 hours from the start of the initial dose of study medication (p=0.0194).

Additional Secondary Efficacy and Safety Findings

The treatment phase of the study began in the post-anesthetic care unit (PACU) after completion of surgery when patients reported a pain intensity score (PI) of at least 2 (moderate pain) on a 4-point verbal rating scale (0 (none) to 3 (severe pain)). The clinical trial study period was up to 12 hours and patients were allowed to self-administer AeroLEF(TM) to treat up to two additional pain episodes during the study period. For each pain episode, patients were instructed to continue the self-administration of drug until achievement of one of the following endpoints: achievement of effective analgesia, completion of full dose, or onset of dose-limiting side effects. Patients were allowed rescue medication at any time following initiation of study treatment.

For the first dose administered in the PACU, the percentage of patients reporting a pain intensity (PI) score of less than or equal to 1 (mild pain or no pain) at the end of the dosing period with AeroLEF(TM) was 59%, a statistically significant difference from placebo (27%)
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
3. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
4. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:6/19/2013)... -- The American Association for Homecare (AAHomecare), along with a ... announced today the filing of a lawsuit in ... asking that the scheduled July 1 expansion of the Medicare ... stopped because of serious licensing irregularities. The lawsuit ... Secretary Kathleen Sebelius as the defendant. HHS oversees ...
(Date:6/19/2013)... 19, 2013 Ellen MacArthur ... kommande tre åren kommer att vara en partner ... cirkulär ekonomi. Efter stiftelsens framgångsrika partnerskap ... Grid, kommer Philips att ansluta sig som partner ... i sin egen verksamhet och stödja stiftelsens arbete ...
(Date:6/19/2013)... , June 19, 2013  Finesse Solutions, Inc, ... life sciences process applications, announced the launch of ... upstream cell culture and fermentation.  The 3L glass ... family of Finesse bioreactors and are designed to ... They are fully compatible with all Finesse G3Lab ...
Breaking Medicine Technology:AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 2AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 3AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 4AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 5Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 2Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 3Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2
... 11, 2011 MedQuist Holdings Inc. (Nasdaq: ... of integrated clinical documentation solutions for the U.S. healthcare ... public offering of shares of its common stock.  The ... NASDAQ Global Market under the ticker symbol MEDH. ...
... Feb. 11, 2011 Vitalitec International, ... of the ENCLOSE II Anastomosis Assist Device from Novare ... was developed by Thomas Fogarty, MD, and is designed ... Bypass Procedures. Vitalitec International, Inc. is a ...
Cached Medicine Technology:MedQuist Holdings Inc. Announces Closing of Its Initial U.S. Public Offering and Acquisition of Additional Shares of MedQuist Inc. 2MedQuist Holdings Inc. Announces Closing of Its Initial U.S. Public Offering and Acquisition of Additional Shares of MedQuist Inc. 3
(Date:6/19/2013)... Philadelphia, Pa. (June 19, 2013) The results of ... issue of Neurosurgery , official journal of the ... is published by Lippincott Williams & Wilkins , ... One study indicates that continuous "machine learning" using artificial ... survival in patients with advanced brain cancers. Another study ...
(Date:6/19/2013)... study reveals significant disparities between minority and white ... treatment programs. Moreover, these disparities vary widely from ... that for most states there,s something amiss," says ... biostatistics. "There are strong racial and ethnic disparities ... abuse treatment programs successfully, and those disparities are ...
(Date:6/19/2013)... Casual, no-strings sexual encounters are increasingly common ... likely than others to "hook up"? A new ... for Behavioral and Preventive Medicine, published online by ... there are certain factors and behaviors associated with ... , "Given the potential for negative emotional and ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Effective Environmental Services ... of new websites. These online links are devoted to a ... Tank cleaner, Organic Odor Control Mold Magician and others. , ... fish and animals in the water as well as living ... sludge buildup that can accumulate at the bottom of a ...
(Date:6/19/2013)... 2013 North Carolina-based life sciences ... to advance development of its technologies. , Entegrion’s ... the advanced development of our product candidates Entegrion’s ... Company’s management structure and engaged industry leaders as ... that Michael Galiger will serve as Vice President ...
Breaking Medicine News(10 mins):Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Why are some college students more likely to 'hook up'? 2Health News:Effective Environmental Services Launch New Websites to Serve Customers 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3
... American Journal of Transplantation reveals that cigarette smoke ... would have been prevented by certain drug treatments. Led ... Health Science Center, researchers used mouse transplant models to investigate ... and its mechanism of action. Seven to eight mice ...
... has shown that removing polyps by colonoscopy not only prevents ... disease. Patients in the study were evaluated for up to ... results to date. The collaborative study, led by researchers at ... 23, 2012 issue of The New England Journal of ...
... WEDNESDAY, Feb. 22 (HealthDay News) --,Toddlers are more likely to ... quickly and overreact to their children,s behavior, according to a ... behavior of adopted children aged 9 months, 18 months and ... 10 states. Researchers also analyzed genetic data from the children ...
... found that insulin production may persist for decades after the ... appears to be preserved in some patients years after apparent ... March issue of Diabetes Care . ... in patients with advanced type 1 diabetes. However, data ...
... HealthDay Reporter , TUESDAY, Feb. 21 (HealthDay News) -- ... sensitivity, but a new analysis suggests that many people who ... Health experts have claimed that this special diet can ... a substance found in wheat, barley, rye and possibly oats. ...
... HealthDay Reporter , TUESDAY, Feb. 21 (HealthDay ... patients with blocked leg arteries, a new European study ... disease, often suffer from intermittent claudication, which is pain ... legs. Animal experiments had suggested that aspirin might block ...
Cached Medicine News:Health News:Colonoscopy prevents deaths from colon cancer 2Health News:Toddlers With Angry Parents May Have More Temper Tantrums 2Health News:Study finds some insulin production in long-term Type 1 diabetes 2Health News:Is Avoiding Gluten in Foods Always Necessary? 2Health News:Is Avoiding Gluten in Foods Always Necessary? 3Health News:Aspirin as Good as Plavix for Poor Leg Circulation: Study 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: